Published in J Antimicrob Chemother on January 01, 2011
Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) (2013) 1.14
Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis (2013) 0.91
Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis (2015) 0.81
Bone suppression increases the visibility of invasive pulmonary aspergillosis in chest radiographs. PLoS One (2014) 0.80
Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. PLoS One (2015) 0.78
Treatment principles for the management of mold infections. Cold Spring Harb Perspect Med (2014) 0.77
Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis (2017) 0.75
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis (2008) 3.18
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother (2003) 1.71
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis (2009) 1.54
Changes in causes of death over time after treatment for invasive aspergillosis. Cancer (2008) 1.46
Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica (2005) 1.44
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood (2003) 1.34
Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res (2013) 1.33
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica (2011) 1.31
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 1.30
Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics (2006) 1.24
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis (2006) 1.22
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer (2007) 1.19
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis (2007) 1.17
The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet (2008) 1.16
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis (2005) 1.15
Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol (2012) 1.11
Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents (2006) 1.10
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res (2010) 1.05
Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol (2002) 1.03
Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis (2003) 1.00
Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab (2009) 0.99
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis (2005) 0.97
Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis (2005) 0.97
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Early proinflammatory cytokines and C‐reactive protein trends as predictors of outcome in invasive Aspergillosis. J Infect Dis (2010) 0.95
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol (2012) 0.95
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Breakthrough invasive mould infections in patients treated with caspofungin. J Infect (2011) 0.93
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother (2004) 0.88
Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics (2008) 0.88
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood (2011) 0.87
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet (2008) 0.86
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J Proteome Res (2009) 0.85
Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature. Med Mycol (2013) 0.85
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses (2010) 0.85
Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother (2012) 0.84
Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol (2010) 0.84
Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol (2009) 0.83
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother (2004) 0.83
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. Pharm World Sci (2009) 0.83
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol (2006) 0.82
Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin. Acta Haematol (2010) 0.82
Poor reporting quality of key Randomization and Allocation Concealment details is still prevalent among published RCTs in 2011: a review. J Eval Clin Pract (2013) 0.81
An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. J Antimicrob Chemother (2013) 0.81
Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol (2010) 0.81
Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol (2011) 0.81
Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res (2006) 0.80
Antifungal combination treatment: a future perspective. Int J Antimicrob Agents (2006) 0.80
Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. J Antimicrob Chemother (2013) 0.80
Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses (2015) 0.79
Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? Clin Infect Dis (2008) 0.79
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.78
13q deletions in B-cell lymphoproliferative disorders: frequent association with translocation. Cancer Genet Cytogenet (2007) 0.78
Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. Eur Radiol (2004) 0.78
Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. Clin Infect Dis (2003) 0.78
Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. Clin Infect Dis (2003) 0.78
Managing the challenges of invasive fungal infections. Int J Antimicrob Agents (2006) 0.78
Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. Trials (2013) 0.77
Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet (2006) 0.76
Allocation concealment: a methodological review. J Eval Clin Pract (2013) 0.76
Mycograb for the treatment of invasive candidiasis. Clin Infect Dis (2006) 0.76
Earlier diagnosis of angioinvasive pulmonary mold disease: is computed tomography pulmonary angiography a new step? Clin Infect Dis (2012) 0.75
Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm (2011) 0.75
Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost (2014) 0.75
[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for early evaluation of treatment efficacy in advanced non-Hodgkin lymphoma of uterine corpus: a case report. Clin Lymphoma Myeloma (2007) 0.75
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis (2006) 0.75
[Post-therapy surveillance in non-Hodgkin's lymphomas]. Rev Prat (2002) 0.75
[Potential clinical impact of therapeutic education in patients treated with anticancer drugs]. Bull Cancer (2011) 0.75
[Lipid formulations of amphotericin B in the management of invasive fungal infections]. Therapie (2006) 0.75
The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. Clin Infect Dis (2004) 0.75